clinical & translational science: individualizing cancer immunotherapy
DESCRIPTION
Clinical & Translational Science: Individualizing Cancer Immunotherapy. Scott A. Waldman, MD, PhD, FCP Thomas Jefferson University. Clinical & Translational Science: Individualizing Cancer Immunotherapy. Scott A. Waldman, MD, PhD, FCP - PowerPoint PPT PresentationTRANSCRIPT
Clinical & Translational Science:Individualizing Cancer ImmunotherapyScott A. Waldman, MD, PhD, FCPThomas Jefferson University
Clinical & Translational Science:
Individualizing Cancer Immunotherapy
Scott A. Waldman, MD, PhD, FCP
Director, Delaware Valley Institute for Clinical and Translational ScienceChair, Department of Pharmacology and Experimental Therapeutics
Director, GI Malignancies Program, Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphia, Pennsylvania
Disclosures• I am the Chair of the Scientific Advisory Board of
Targeted Diagnostics & Therapeutics, Inc. (TDT; uncompensated)
• TDT provides research support to my laboratory• TDT licenses patents which are the subject of this
presentation• This technology has been sublicensed to
DiagnoCure, which does not provide support for this work
• I am entitled to a share of royalties collected by Thomas Jefferson University upon the sale of products resulting from patents on which I am an inventor
Delaware Health Sciences Alliance
Delaware Valley Institute for Clinical and Translational Science (DVICTS)
Translational Investigators
Colorectal Cancer and Women
Stage, Prognosis and Prediction
% of cases at presentation
Stage I Stage II Stage III Stage IV
% 5 yearsurvival
14
89 64 38 3
28 37 21
Stage
Recurrence (%)
20 40
Caucasian
African American
The One-Two Punch:Finding and Eradicating Occult Metastases
Guanylyl Cyclase C (GCC) as a Marker and Target in Colon Cancer
N T F Y C C E L C C N P A C A G C Y
The First Punch:Identifying Patients with Occult Metastases
Identifying Patients With Occult Metastases Using Molecular Detection
Low Risk (<5%)
High Risk (>80%)Hazard Ratio=65
The Second Punch:Eliminating Occult Metastases
Novel Vaccine Approaches to Colon Cancer: Cancer Mucosal Antigens
1
2
Tcell
APC
Cancer Mucosa Antigens
5 X
CRC Metastase
s
Effector T cells
43
20 30 400
20
40
60
80
100 ControlGCC
p<0.001
Days
Perc
ent S
urvi
val
Control GCC0
100
200
300
400
***
Immunization
Tum
or N
umbe
r
GCC Vaccine Protects Against Metastatic Colon Cancer in Mice
Individualizing Cancer Immunotherapy
20 30 400
20
40
60
80
100 ControlGCC
p<0.001
Days
Perc
ent S
urvi
val
AcknowledgementsThomas Jefferson University and Kimmel Cancer Center· Pharmacology
Stephanie Schulz Peng Li Janis Haaf Chris Bonaccorso Egeria Lin Ahmara Gibbon Michael
Valentino David Zuzga Adam Snook Alex Meija
• Medical Oncology Edith Mitchell
• Pathology Juan Palazzo
· Biostatistics Terry Hyslop
· Surgery Scott Goldstein Gerald Isenberg
Christiana Care Bruce Boman Nicholas Petrelli
Funding NIH PA
Department of Health
TDT, Inc.